Page 29 - MONOGRAFIA 25, de Esclerosis multiple

VIRUS
01
BIBLIOGRAFÍA
1. Geginat J, Paroni M, Pagani M, Galimberti D, De Francesco R, Scarpini E, Abrignani S. The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance? Trends Immunol. 2017;38:498-512.
2. Mentis AA, Dardiotis E, Grigoriadis N, Petinaki E, Hadjigeorgiou GM. Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Mol Neurobiol. 2017;54:3911-23.
3. Almohmeed YH, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS One. 2013;8:e61110.
4. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One. 2010;5:e12496.
5. Giovannoni G. Multiple sclerosis: the environment and causation. Curr Opin Neurol. 2007;20:261-8. 6. Ascherio A. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann
Neurol. 2007;61:288-99.
7. Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, et al. Elevated Epstein-Barr
virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann
Neurol. 2010;67:159-69.
8. Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases
of multiple sclerosis and may engage more than just B cells. PLoS One. 2018;13:e0192109.
9. Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 2012;78:15-23. 10. Najafipoor A, Roghanian R, Zarkesh-Esfahani SH, Bouzari M, Etemadifar M. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Cell Immunol. 2015;294:9-12.
11. Ablashi D, Agut H, Álvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, et al. Classification of
HHV-6A and HHV-6B as distinct viruses. Arch Virol. 2014;159:863-70.
12. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A. 1995;92:7440-4. 13. Leibovitch EC, Jacobson S. Viruses in chronic progressive neurologic disease. Mult Scler.
2018;24:48-52.
14. Ben-Fredj N, Ben-Selma W, Rotola A, Nefzi F, Benedetti S, Frih-Ayed M, et al. Prevalence of human
herpesvirus U94/REP antibodies and DNA in Tunisian multiple sclerosis patients. J Neurovirol.
2013;19:42-7.
15. García-Montojo M, De Las Heras V, Domínguez-Mozo M, Bartolomé M, García-Martínez MA,
Arroyo R, et al. Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis
patients. Eur J Neurol. 2011;18:1027-35.
16. Ortega-Madueño I, García-Montojo M, Domínguez-Mozo MI, García-Martínez A, Arias-Leal
AM, Casanova I, et al. Anti-human herpesvirus 6A/B IgG correlates with relapses and progression
in multiple sclerosis. PLoS One. 2014;9:e104836.
17. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S. Increased lymphoproliferative response
to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol. 2000;47:306-13.
29